European Pharmaceutical Review

DECEMBER 18, 2023

Pharmaceutical manufacturing Oligonucleotides Last month, the Centre for Process Innovation (CPI) announced a new Scotland-based manufacturing facility focusing on oligonucleotide therapeutics. According to CPI, the facility is set to be completed in late 2025.

Manufacturing 98

Manufacturing Food and Drug Administration Medicine Pharmaceutical manufacturing 98

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting.

Pharmaceutical 94

Pharmaceutical Manufacturing Medicine Competition 94

PM360

AUGUST 9, 2022

billion in 2025. The FDA 510(k) submission is expected to take place in Quarter 3 2023. Launched in July 2021, Prescryptive Health provides next-generation, mobile market access and medication adherence solutions for pharmaceutical manufacturers. from 2021 and reach $4.2 Furthermore, it is estimated to reach $6.5

Prescription 105

Prescription Medical Patients Side effects 105

Clarivate

AUGUST 20, 2024

In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. drugs more recently approved by the FDA, those with an orphan drug designation for a single indication, or those facing current or looming biosimilar threat) can escape negotiations. That compares to the $240.4

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52